SPX3,911.74+116.01 3.06%
DIA315.02+8.28 2.70%
IXIC11,607.62+375.43 3.34%

Fulcrum Says Initial Data From Phase 1b Trial Backs FTX-6058 for Treatment in Sickle Cell Disease

MT Newswires · 06/10/2022 03:50

Please log in to view news